Four catalogue blends and one process-defined preparation raise the same question: what does a study of an ingredient tell you about a product that contains it? Less than it seems.
Research on a single defined compound produces evidence about that compound, in that model, by that route. Put two compounds in one vial and a new question appears: what does the mixture do? For the blends in this catalogue that question has not been answered: the closest thing is one small, uncontrolled report of two of the ingredients given as separate injections. This guide explains why ingredient evidence does not add up, and what the word ‘protocol’ does and does not mean on a label.
Pulse sells four combined products. BPC + TB Blend contains BPC-157 and TB-500, the latter identified as full-length thymosin beta-4 in independent batch testing. CJC + IPA Blend contains CJC-1295 without DAC (modified GRF 1-29, per batch testing) and ipamorelin, 5 mg of each. GLOW contains TB-500 10 mg, BPC-157 10 mg and GHK-Cu 50 mg. KLOW contains the same three plus KPV 10 mg. (The BPC + TB Blend’s labelled split between the two components is being confirmed against its batch report.)
Each ingredient has a research note of its own. What none of them has is a study of the finished blend. The nearest published item is a retrospective chart review of 16 knee-pain patients at one US clinic, four of whom had received BPC-157 and thymosin β4 as separate intra-articular injections, with self-reported relief and no control group (Lee and Padgett 2021). That is co-administration in a case series, not a controlled trial, and not a test of a premixed vial. No study of the CJC + IPA, GLOW or KLOW mixtures was identified.
Take GLOW. The BPC-157 evidence is rat tendon, muscle and gut injury, by intraperitoneal injection, within minutes of a surgical cut (Staresinic et al. 2003). The thymosin beta-4 evidence is mouse skin wounds and a mouse heart-attack model, by topical and injected routes (Malinda et al. 1999), plus one human eye-drop trial. The GHK-Cu human evidence is a gel applied to diabetic foot ulcers (Mulder et al. 1994). Three species, three routes, three injuries, three endpoints. There is no experiment those results describe in common, and adding KPV, whose evidence is oral delivery to inflamed mouse colon, does not create one.
CJC + IPA Blend is the cleaner case because both ingredients act on the pituitary. Even so, the human data for CJC-1295 concern the DAC form (Teichman et al. 2006) and the blend contains the form without DAC, which has no equivalent trials; ipamorelin’s selectivity was shown in rat cells and pigs (Raun et al. 1998), and its one randomised trial was in bowel surgery. Two receptors on one gland is a reason to hypothesise an interaction. It is not an observation of one.
The contrast is REDEFINE 1, the trial of cagrilintide with semaglutide (Garvey et al. 2025). It gave two pharmaceutical products together at defined doses, randomised 3,417 adults to the combination, each component alone, or placebo, and measured a pre-specified endpoint over 68 weeks. That design lets a reader see what the mixture added beyond its parts, and what it cost in adverse events. It also shows the limit: that evidence belongs to that pairing, and does not transfer to cagrilintide with anything else.
Nothing resembling that design exists for any blend in this catalogue. Until it does, a blend is a set of untested hypotheses in one vial, one for each interaction its components might have.
Cerebrolysin is a different kind of mixture. It is not two known peptides combined but a preparation of many small peptides and amino acids produced by enzymatic breakdown of pig brain protein. It has no single structure; its identity is the manufacturing process. That is why its evidence, mainly human trials of the branded intravenous solution in stroke and vascular dementia, is so hard to transfer. The 2023 Cochrane review of seven stroke trials found the preparations probably make little or no difference to death and probably increase non-fatal serious adverse events (Ziganshina et al. 2023).
A lyophilised powder sold under the same name is a different presentation. Whether it matches the trialled solution cannot be assumed without characterisation of the specific batch, and a purity figure does not capture the composition of a process-defined mixture.
GLOW and KLOW are catalogue names for fixed mixtures. A product name does not denote a clinically established regimen, a published trial or any tested sequence of use; the composition beneath the name is what a reader can check.
Sources checked 2026-09-22